Helus Pharma's HLP003 meets primary endpoint in Phase 3 APPROACH depression trial
Topline data show the deuterated psilocin candidate improved MADRS scores versus placebo as adjunctive therapy in adults with major depressive disorder, with a second pivotal readout due in Q4 2027.
Helus Pharma reported on 16 November 2026 that HLP003, its deuterated psilocin candidate, met the primary endpoint in the Phase 3 APPROACH trial. The study tested the product as an adjunctive treatment in adults with major depressive disorder (MDD).
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Helus Pharma Inc. ↗
Article written by VigiEye from the official source (Helus Pharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.